Foresite Labs, LLC

10% owner Foresite Labs buys 411,764 shares for $7.0M at $17.00 on 2026-01-08; stock +83.6% in 30 days post-transaction amid unprofitable operations.

Foresite Labs executed 2 separate purchases totaling 411,764 shares for $6,999,988.00 at $17.00 per share on 2026-01-08, increasing its holdings by 16.5% to 2,908,332 shares. This substantial capital commitment ($7.0M) comes as the stock has rallied 83.6% in the 30 days following the transaction and trades at $21.09, matching its 52-week high. The purchase occurs within a tight cluster of 4 insider buys across 14 days. However, this bullish activity is offset by deteriorating fundamentals: Alumis reported quarterly revenue of $2,066,000 and net loss of $-110,752,000, underscoring the company's unprofitable status. The 10% owner's track record across all holdings shows a 90-day win rate of 0.00%, and his prior ALMS transactions (5 buys in mid-November) remain too recent to measure 90-day outcomes, leaving open whether near-term price strength reflects sustainable business improvement or momentum-driven repricing.

Foresite Labs (10% owner) bought 72,212 shares of ALMS at $7.38; 4 buys in 5 days amid -$110.8M net loss.

Foresite Labs purchased 72,212 shares on 2025-11-21 at $7.38, expanding its stake to 2,614,215 shares (+2.8% from pre-transaction holdings). This transaction is one of five purchases at ALMS within five days (2025-11-17 through 2025-11-21), alongside a cluster of 3 other insiders buying within the past 14 days. The timing occurs within a volatile price environment: ALMS is currently $7.33 (-27.2% from its 52-week high of $10.07) but +62.5% over the last 30 days. However, the company reported a net loss of -$110,752,000.00 in its most recent full fiscal year and a latest quarterly revenue of only $2,066,000.00, signaling severe unprofitability. Foresite Labs' cross-ticker track record shows 0% accuracy at the 90-day mark across 8 prior open-market buys (average 90d return -19.2%), and its one measurable prior trade at ALMS (2025-05-06) generated a -5.8% 90-day return. The rapid succession of insider purchases against deteriorating fundamentals and poor historical timing outcomes presents a complex signal: coordinated accumulation may reflect conviction in near-term recovery, but the insider's track record and the company's financial distress warrant caution.

Foresite Labs (10% owner) bought 507,874 shares at $5.60–$6.56 for $3,094,725.06; now holds 2,542,003 shares (+25.0%).

Foresite Labs executed 4 separate purchases totaling 507,874 shares for $3,094,725.06 (blended average $6.09) over three trading days, increasing its stake by 25.0% to 2,542,003 shares post-transaction. The timing is notable: this represents a cluster activity alongside 3 other insiders who bought within the past 14 days, and the stock has posted a +38.0% 30-day return and +42.8% 90-day return off a depressed base ($2.80–$10.35 range). However, the broader pattern is concerning: Foresite Labs' same-ticker history at ALMS shows 0 of 4 prior buys were well-timed at the 90-day mark, with prior purchases yielding average 90-day returns of -5.8%, -10.4%, -30.2%, and -30.2%. The company's fundamentals are weak (revenue $2,066,000.00 latest quarter; net income $-110,752,000.00 unprofitable for the most recent full fiscal year), and the current price of $6.57 remains -36.5% from the 52-week high. The concurrent cluster buying and recent strong price momentum contrast sharply with the insider's historical underperformance and the company's unprofitable operating position.

10% owner Foresite Labs acquires 45,000 shares ($202.3K) across 2 purchases; stock down -67.3% from 52-week high amid -$93.1M annual loss.

Foresite Labs, a 10% owner, executed 2 separate purchases totaling 45,000 shares for $202,300.00 at prices of $4.62 and $4.34 between May 2–6, 2025, increasing holdings to 4,247,670 shares. The purchases occurred as the stock trades at $4.35, down -56.7% over 30 days and -67.3% from its 52-week high of $13.30. The company reported net income of -$93,117,000.00 for its most recent full fiscal year, indicating ongoing unprofitability. Notably, Foresite's prior 2 purchases at ALMS, both on 2024-07-01, each returned -23.1% over 30 days and -30.2% over 90 days, with 0 of 2 prior buys meeting the 90-day win-rate threshold. The timing pattern and negative historical returns at this same ticker warrant attention to whether current accumulation reflects conviction or continuation of a pattern of purchases made at inopportune moments.

Foresite Labs buys 2,500,000 shares (2.50M) for $40,000,000 at $16.00; cluster pattern with 2 other insiders buying in past 14 days

Foresite Labs, a 10% shareholder, executed 2 separate purchases totaling 2,500,000 shares for $40,000,000.00 at $16.00 per share on 2024-07-01, expanding its stake from 1,702,670 shares to 4,202,670 shares (a 146.8% increase). The transaction occurred just 4 trading days after the company's recent IPO listing. This filing represents part of a broader cluster pattern: 2 other insiders also purchased within the past 14 days, suggesting coordinated board or insider interest in accumulating shares at the IPO price. The subsequent market price of $11.65 as of 2024-07-03 is materially below the $16.00 transaction price, indicating the position has moved underwater in the immediate aftermath. Investors should monitor whether this large capital commitment and the clustering of insider purchases reflect management's view of intrinsic value, or whether post-IPO dynamics are shaping near-term price discovery.